These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30099753)

  • 1. Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.
    Ferlito C; Biselli R; Cattaruzza MS; Teloni R; Mariotti S; Tomao E; Salerno G; Peragallo MS; Lulli P; Caporuscio S; Autore A; Bizzarro G; Germano V; Biondo MI; Picchianti Diamanti A; Salemi S; Nisini R; D'Amelio R
    Clin Exp Immunol; 2018 Dec; 194(3):361-370. PubMed ID: 30099753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
    Dbaibo G; Van der Wielen M; Reda M; Medlej F; Tabet C; Boutriau D; Sumbul A; Anis S; Miller JM
    Int J Infect Dis; 2012 Aug; 16(8):e608-15. PubMed ID: 22704725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical immunogenicity study of trivalent meningococcal AWX-OMV vaccines for the African meningitis belt.
    Tunheim G; Naess LM; Acevedo R; Fjeldheim ÅK; Bolstad K; García L; Cardoso D; Aase A; Zayas C; González H; Rosenqvist E; Norheim G
    Vaccine; 2014 Nov; 32(49):6631-8. PubMed ID: 25305564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEG as a spacer arm markedly increases the immunogenicity of meningococcal group Y polysaccharide conjugate vaccine.
    Huang Q; Li D; Kang A; An W; Fan B; Ma X; Ma G; Su Z; Hu T
    J Control Release; 2013 Nov; 172(1):382-389. PubMed ID: 23511718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?
    Tsai TF; Borrow R; Gnehm HE; Vaudaux B; Heininger U; Desgrandchamps D; Aebi C; Balmer P; Pedersen RD; Fritzell B; Siegrist CA
    Clin Vaccine Immunol; 2006 Aug; 13(8):854-61. PubMed ID: 16893984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial.
    MacDonald NE; Halperin SA; Law BJ; Forrest B; Danzig LE; Granoff DM
    JAMA; 1998 Nov; 280(19):1685-9. PubMed ID: 9832000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody avidity and immunoglobulin G isotype distribution following immunization with a monovalent meningococcal B outer membrane vesicle vaccine.
    Vermont CL; van Dijken HH; van Limpt CJ; de Groot R; van Alphen L; van Den Dobbelsteen GP
    Infect Immun; 2002 Feb; 70(2):584-90. PubMed ID: 11796586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone.
    Broderick MP; Romero-Steiner S; Rajam G; Johnson SE; Milton A; Kim E; Choi LJ; Radin JM; Schmidt DS; Carlone GM; Messonnier N; Faix DJ
    Clin Vaccine Immunol; 2016 Aug; 23(8):672-80. PubMed ID: 27280619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults.
    de Voer RM; van der Klis FR; Engels CW; Schepp RM; van de Kassteele J; Sanders EA; Rijkers GT; Berbers GA
    Vaccine; 2009 Nov; 27(50):6974-82. PubMed ID: 19800445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of meningococcus serogroup C conjugate vaccine administered as a primary or booster vaccination to healthy four-year-old children.
    McVernon J; Maclennan J; Buttery J; Oster P; Danzig L; Moxon ER
    Pediatr Infect Dis J; 2002 Aug; 21(8):747-53. PubMed ID: 12192163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
    Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
    Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderate PEGylation of the carrier protein improves the polysaccharide-specific immunogenicity of meningococcal group A polysaccharide conjugate vaccine.
    Zhang T; Yu W; Wang Y; Hu T
    Vaccine; 2015 Jun; 33(28):3208-14. PubMed ID: 25964170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger K; Blatter MM; Quataert SA; Madore DV; Chang I; Malinoski FJ; Hackell JG; Paradiso PR
    Pediatr Infect Dis J; 2001 Feb; 20(2):153-9. PubMed ID: 11224833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetravalent meningococcal polysaccharide vaccine is immunogenic in adult allogeneic BMT recipients.
    Parkkali T; Käyhty H; Lehtonen H; Ruutu T; Volin L; Eskola J; Ruutu P
    Bone Marrow Transplant; 2001 Jan; 27(1):79-84. PubMed ID: 11244441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine.
    Leach A; Twumasi PA; Kumah S; Banya WS; Jaffar S; Forrest BD; Granoff DM; LiButti DE; Carlone GM; Pais LB; Broome CV; Greenwood BM
    J Infect Dis; 1997 Jan; 175(1):200-4. PubMed ID: 8985221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.